Cost Effectiveness of Influenza Vaccination in Older Adults

@article{Newall2012CostEO,
  title={Cost Effectiveness of Influenza Vaccination in Older Adults},
  author={A. Newall and H. Kelly and S. Harsley and Prof. Paul A. Scuffham},
  journal={PharmacoEconomics},
  year={2012},
  volume={27},
  pages={439-450}
}
  • A. Newall, H. Kelly, +1 author Prof. Paul A. Scuffham
  • Published 2012
  • Medicine
  • PharmacoEconomics
  • AbstractSeveral recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50–64 years. We identified and reviewed all costeffectiveness studies of influenza vaccination in those aged 50–64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates… CONTINUE READING

    Tables and Topics from this paper.

    Economic Evaluations of Childhood Influenza Vaccination
    • 20
    Economic value of influenza vaccination
    • 19

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES
    Mortality benefits of influenza vaccination in elderly people: an ongoing controversy.
    • 488
    • Highly Influential
    • PDF
    Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    • 262
    • PDF
    Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
    • 123
    • Highly Influential
    The Efficacy of Influenza Vaccine in Elderly Persons
    • 1,086
    • Highly Influential
    The economic impact of pandemic influenza in the United States: priorities for intervention.
    • 533
    • PDF
    Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    • 93
    The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    • 69
    • Highly Influential
    The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.
    • 59
    • Highly Influential